Container closure integrity testing (CCIT) verifies that a sealed pharmaceutical container, such as a vial or syringe with its closure, will keep out contaminants and keep in product for the life of the container. Because regulators require validated leak-detection methods for sterile products, companies patent both the physical test apparatus and the validation methodology itself. That dual focus is why this dataset's records cluster almost entirely in G01M, the testing-machinery classification, rather than spreading across packaging design classes.

In this dataset of 18 records, the ranking of 8 assignees is led by Lonza with 8 records, a steep step down to the next tier of filers, and a long tail of single-record filers including named individual inventors. This concentration means a competitive review should weight the leader's filings heavily rather than treating the field as evenly contested. Smaller filers still matter where their specific claims overlap a planned product or method.

Filing activity in this dataset peaked in 2018 at 6 records and has not returned to that level since, with no completed filings recorded in the most recent full years. A formal growth rate cannot be computed from this evidence because fewer than four complete years remain once the roughly 18-month publication lag is accounted for. Readers should treat the most recent one to two years as understated rather than genuinely quiet.

US20200271541A1, filed by Lonza and published in 2020, describes devices and methods for testing the leak-tightness of a two-part pharmaceutical container and closure system, such as a vial and its lid, for quality-control purposes. It is the most-cited document in this dataset at 23 citations, which signals strong influence over how later applicants have framed their own claims. Anyone designing a new CCIT method or apparatus for a similarly structured container should read its specific claim language before finalising a design, since overlap risk is highest wherever the test mechanism and container geometry resemble what it describes.

The clearest gaps sit at the edges of the dense G01M core: only 5 of the 18 records touch A61M body-fluid device claims and just 1 touches A61J medicine-container claims, both far below the 100% density seen in the core testing-apparatus classification. Sampling-scheme and defect-standard methodology, named directly in the search criteria, also show thin coverage relative to the apparatus claims. These adjacent, lower-density branches are the more promising areas to scope a new filing rather than the crowded core.